Form 4: NEA 18 Venture Growth Equity Acquires Warrants in NeueHealth, Inc.

NEA 18 Venture Growth Equity, L.P. reports acquisition of warrants to purchase 371,187 shares of NeueHealth, Inc. common stock.

Summary

• NEA 18 Venture Growth Equity, L.P. filed a Form 4 disclosing the acquisition of warrants for NeueHealth, Inc. common stock on April 8, 2024.
• The warrants, exercisable after the 'Closing Date' (defined as the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual), allow the purchase of 371,187 shares at $0.01 per share.
• The warrants are exercisable until the fifth anniversary of the Closing Date.
• The filing also identifies NEA Partners 18 VGE, L.P., NEA 18 VGE GP, LLC, and individual managers as indirect holders, who disclaim beneficial ownership except to the extent of their pecuniary interest.
• The warrants are issued pursuant to a Warrantholders Agreement and a Credit Agreement, as amended.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of warrants suggests confidence in the company's future, but it's a standard financial transaction.

Positives

• The acquisition of warrants by NEA 18 Venture Growth Equity, L.P. could be seen as a positive signal, indicating investor confidence in NeueHealth's future prospects.
• The low exercise price of $0.01 per share provides a significant potential upside for the warrant holder.

Risks

• The value of the warrants is dependent on the future performance of NeueHealth's stock price.
• The 'Closing Date' is contingent on the distribution of a letter to shareholders, introducing some uncertainty regarding the exact timing of warrant issuance.

Future Outlook

The warrants are exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date, implying a long-term investment horizon for NEA 18 Venture Growth Equity, L.P.

Management Comments

• The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Indirect Reporting Persons have no pecuniary interest.

Industry Context

Venture capital firms like NEA frequently use warrants as part of financing agreements, providing them with potential upside while mitigating risk. This investment reflects ongoing interest in the healthcare technology and services sector, where NeueHealth operates.

Comparison to Industry Standards

• Warrant agreements are a common tool used by venture capital firms like NEA, Accel, and Kleiner Perkins to invest in growth companies.
• The specific terms of the warrant agreement, such as the exercise price and expiration date, are typical for venture financings.
• Similar transactions can be seen in other healthcare technology companies that have received venture funding.

Stakeholder Impact

• Shareholders may view the warrant acquisition as a positive sign, potentially leading to increased investor confidence.
• The transaction could provide NeueHealth with additional capital if the warrants are exercised in the future.

Next Steps

• The warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.
• NEA 18 Venture Growth Equity, L.P. will monitor NeueHealth's performance and may exercise the warrants depending on market conditions and the company's progress.

Key Dates